Immuno oncology News and Research

RSS

Cleveland Clinic’s ROBIN center may pave way for more effective radiation, immunotherapy treatments

Cleveland Clinic received a $7.9 million five-year grant from the National Cancer Institute at the National Institutes of Health to form one of three national centers as part of the newly established Radiation Oncology-Biology Integration Network (ROBIN).

22 Sep 2022

MD Anderson and Virogin Biotech partner to accelerate the development of investigational treatments for advanced cancers

The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.

7 Sep 2022

Peter Adams and Bing Ren receive NIH grant to join multi-institution initiative studying the aging process

Peter Adams, Ph.D., and Bing Ren, Ph.D., have been awarded a new grant from the National Institutes of Health (NIH) to join a multi-institution initiative studying the process of aging.

16 Aug 2022

Researchers reveal important factor behind cancer therapy resistance and a way to counter it

Why doesn't every cancer patient respond to immunotherapy? That's the question that researcher Daniel Peeper is looking to answer.

9 Jun 2022

UCLA researchers identify a method to make tumors susceptible to immune attack

One powerful way cancer cells defend against tumor-killing immune cells is to load up their cell surface with a protein known as PD-L1. Now a team of UCLA Jonsson Comprehensive Cancer Center researchers led by Roger S. Lo, MD, PhD, has identified a method to degrade tumor cell-surface PD-L1, thereby making tumors susceptible to immune attack.

31 May 2022

Blood-based biomarker can predict the benefit of immunotherapy to lung cancer patients

A blood-based tumor biomarker can predict the benefit of immunotherapy to patients with non-small cell lung cancer, according to a study published in Nature Medicine.

20 May 2022

First patient dosed in Phase 1 clinical trial evaluating the safety of CF33-hNIS against solid tumors

Imugene Limited, a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors.

18 May 2022

Breakthrough finding reveals how male sex hormones contribute to cancer-related sex bias

Patients with cancers stemming from non-reproductive organs, such as bladder and liver cancer, have striking discrepancies in incidence, progression, response to treatment and survival outcomes depending on their sex. In almost all cases, male patients have worse prognoses and outcomes.

15 Apr 2022

Unique immune cell fingerprint can help rapidly identify better treatment for autoimmune disease

Most autoimmune diseases are easy to diagnose but hard to treat. A paper published today in Science proposes using your unique immune cell fingerprint to rapidly identify which treatments will work for your autoimmune disease.

7 Apr 2022

Bruker introduces Ultima Investigator Plus — Multiphoton microscope for tissue imaging

Bruker today announced the release of the Ultima Investigator Plus, the newest modular platform addition to the industry-leading Ultima line of multiphoton microscopes for deep tissue fluorescence imaging.

From Bruker Nano Surfaces and Metrology 30 Mar 2022

New approach radically increases the success of breast cancer immunotherapy

A study published in the journal Nature Cancer, carried out within the Cancer Programme at the Hospital del Mar Medical Research Institute (IMIM-Hospital del Mar) by the Cancer Stem Cells and Metastasis Dynamics Laboratory, led by Dr. Toni Celià-Terrassa, and the Laboratory of Molecular Cancer Therapy, coordinated by Dr. Joan Albanell, with the participation of international centers, has discovered an approach that radically increases the success of immunotherapy in one of the most aggressive types of tumors, triple-negative breast cancer.

17 Mar 2022

New analysis highlights growing trends in combination cancer therapy clinical trials

The Cancer Research Institute, a nonprofit organization dedicated to the discovery and development of powerful immunotherapies for all types of cancer, announced today the publication of its newest analysis of the global landscape of clinical development of drugs that target the PD1/PDL1 immune checkpoint pathway.

10 Feb 2022

Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Preliminary findings from Penn Medicine in an ongoing first-in-human clinical trial examining the safety, tolerability and feasibility of chimeric antigen receptor macrophage (CAR-M) has helped to establish the viability of this innovative immunotherapy, which advances the trailblazing scientific discovery of CAR T cell therapy- also pioneered at Penn- for solid cancer tumors and offers a promising new strategy in the fight against cancer.

11 Jan 2022

Researchers study immune cell invasion process in living fruit fly embryos

To fight infections and heal injuries, immune cells need to enter tissue. They also need to invade tumors to fight them from within.

6 Jan 2022

Johns Hopkins astrophysicist receives Life Sciences 2021 award for novel cancer mapping technology

Johns Hopkins astrophysicist, Alexander Szalay, Ph.D., and Kimmel Cancer Center pathologist Janis Taube, M.D., M.Sc., received a Life Sciences 2021 award for AstroPath at this year's Falling Walls Science Summit, an international event honoring research breakthroughs from across the globe.

9 Dec 2021

Canopy Biosciences launches the first of a series of targeted assay kits for ChipCytometry

Canopy Biosciences, a Bruker Company, today announced the launch of a first in a series of assay kits for ChipCytometry, a quantitative, high dynamic range and high-resolution multiplexing technology for spatial proteomics.

From Bruker Nano Surfaces and Metrology 8 Dec 2021

Lunaphore to host inaugural Spatial Biology Week™ virtual meeting

Lunaphore today announced the events and activities planned around the inaugural Lunaphore Spatial Biology Week™, taking place virtually December 6-10, 2021.

From Lunaphore 7 Dec 2021

Cerba Research Expands U.S. Immuno-Oncology Center of Excellence to Strengthen Its Precision Medicine Offerings

Cerba Research recently expanded. Our U.S. Immuno-Oncology Center of Excellence allows us to provide even more comprehensive, integrated central lab services, specialty lab and biomarker solutions, and diagnostic services worldwide.

From Cerba Research 25 Nov 2021

Immune checkpoint inhibitor therapy results in longer treatment-free survival for patients with advanced renal cell carcinoma

Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy) experienced longer treatment-free survival (TFS) over a 42-month period than patients who received the targeted therapy sunitinib (Sutent), regardless of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group, according to new analysis of the CheckMate-214 clinical trial.

10 Nov 2021

Lung cancer-associated fibroblasts could guide the design of personalized treatments

Three subtypes of cancer-associated fibroblasts (CAF) could guide the design of personalized treatment for lung cancer patients, according to a new study in Cancer Cell led by researchers at Massachusetts General Hospital.

26 Oct 2021